免疫学博士专业
Doctoral Program in Immunology 导师介绍 Supervisor Profiles
王革非 Gefei Wang
邮箱及联系电话：gefeiwang@stu.edu.cn, 86-754-88900840, 86-13790814697
Email & Contact Number: gefeiwang@stu.edu.cn,86-754-88900840,86-13790814697
研究方向：抗病毒免疫学
Research Field：Antivirus immunology
导师简介 Biography：
王革非，免疫学专业教授、博士生导师。汕头大学医学院病原与免疫学研究中心 主任。在汕头大学医学院微生物学与免疫学教研室、广东省感染病与分子免疫病 理重点实验室从事教学与科研工作。研究方向涉及病毒性脑病脑炎的发病机制与 防治研究；神经胶质细胞在自身免疫与抗感染中的免疫病理效应；流感病毒及肠 道病毒的黏膜免疫研究；呼吸道菌群在感染及黏膜免疫中的作用等。主持国家自 然科学基金 2 项 、广东省自然科学基金及其它课题多项；入选国际脑研究组织 IBRO 青年研究学者计划 、扬帆计划培养高层次人才 、广东高校优秀青年教师计 划 、广东省千百十工程校级培养对象等 。 以第一或通讯作者发表论文 60 余篇，
其中在 Cell Mol Immunol 、Curr Opin Neurol 、J Neuroinflamm、Vaccine 等杂志上 发表 SCI 论文 20 余篇。获得国家发明专利证书 6 项。承担本科生“感染与免疫 ” 模块及医学微生物学与医学免疫学的教学工作，以及硕士研究生及博士研究生免 疫学专业课的教学工作。曾获全国医学院校教学基本功比赛一等奖，广东省高校 青年教师教学大赛二等奖。
Gefei Wang, professor of immunology and doctoral supervisor, is the director of pathogen and Immunology Research Center, Medical College of Shantou University. He is engaged in teaching and scientific research in the Department of Microbiology and immunology, Medical College of Shantou University and the Key Laboratory of infectious diseases and molecular immunopathology of Guangdong Province. His research direction involves the pathogenesis, prevention and treatment of viral encephalitis; immunopathological effects of glial cells in autoimmunity and anti-infection; mucosal immunity of influenza virus, enterovirus and SARS-cov-2; the role of respiratory flora in infection and mucosal immunity. The research has been supported by several funds including 2 projects of National Natural Science Foundation of China, 3 projects of Guangdong Natural Science Foundation, and other funds. Pro. Wang has been selected into IBRO young researchers ’ program, Sail
program to train high-level talents, Excellent young teachers ’ program of Guangdong universities, and school level talents cultivated by “Thousand-Hundred-Ten" Program of Guangdong Province. As the first author or corresponding author, he has published more than 60 papers, including more than 20 SCI papers in Cell Mol Immunol, Curr Opin Neurol, J Neuroinflamm, Vaccine and other magazines; and obtained 6 China National invention patents. Pro. Wang also undertakes the medical microbiology and medical immunology teaching tasks of "infection and immunity" module for undergraduates, as well as immunology courses for master and doctoral students. He has won the first prize in the national basic teaching skills competition of medical colleges, the second prize in young college teachers ’ teaching competition of Guangdong Province.
李蕊 Rui Li
邮箱及联系电话：07rli1@stu.edu.cn, 86-754-88900840, 86-13790852445
Email & Contact Number：07rli1@stu.edu.cn, 86-754-88900840, 86-13790852445
研究方向：抗感染免疫和分子疫苗设计
Research Field：Anti-infective immunity and molecular vaccine design
导师简介 Biography：
李蕊，汕头大学医学院微生物学与免疫学教研室副教授。研究方向涉及肠道病毒 及新型冠状病毒的分子疫苗设计；呼吸道菌群在感染后黏膜免疫中的作用等。主 持国家自然科学青年基金 1 项、广东省及汕头市课题各一项。以第一或通讯作者 发表 SCI 论文 6 篇。获得国家发明专利证书 2 项。承担本科生“感染与免疫”模块 及医学微生物学与医学免疫学的教学工作，以及硕士研究生及博士研究生免疫学 专业课的教学工作。
Rui Li is an associate professor of the Department of Microbiology and Immunology, Shantou University Medical College. Her research focuses on molecular vaccine designing of enterovirus and SARS-cov-2 for mucosal immunity, and the role of respiratory tract flora in mucosal immunity after infection. Including National Natural Science Foundation of China Youth Fund, her research has been supported by 3 project grants. Dr. Li has published 5 SCI papers in Cell Immunol, Vaccine, Front Microbiol and other magazines; and obtained 2 China National invention patents. Dr. Li also undertakes the “medical microbiology” and “medical immunology” teaching tasks of "infection and immunity" module for undergraduates, as well as immunology courses for master and doctoral students.
覃青松 Qingsong Qin
邮箱及联系电话：qsqin@stu.edu.cn, 86-0754-88900474
Email & Contact Number：qsqin@stu.edu.cn, 86-0754-88900474
研究方向：
EBV 相关胃癌是一种独特的亚型，定义为 EBV 潜伏感染的癌细胞的单克隆增殖。 我实验室主要研究 EB 病毒在癌症发生中的作用。EBV 编码的 miRNAs、cirRNAs 和潜伏蛋白（EBNA1、LMP2A）在 EBV 相关的上皮恶性肿瘤中高度表达，可能 诱导恶性转化 。EBV 编码的基因产物可能具有抗凋亡特性 ，促进癌前上皮细胞 的存活 。多种 EBV 编码的微 RNA 具有免疫逃避功能 。EBV 基因表达调控可以 引起宿主细胞的遗传改变，可能与感染的癌前上皮细胞的生长特性有关。我们研 究的目的是寻找 EBV 相关胃癌潜在生物标志物为癌症治疗的提供依据。
Research Field：
EBV associated gastric cancer is a distinct subtype defined by monoclonal proliferation of carcinoma cells with latent EBV infection. My lab is interested in studying the role of Epstein-Barr virus (EBV) in carcinogenesis. EBV encoded miRNAs, cirRNAs, and latent proteins（ EBNA1, LMP2A） are highly expressed in EBV-associated epithelial malignancies and may induce malignant transformation. EBV-encoded gene products may confer anti-apoptotic properties and promote the survival of infected premalignant epithelial cells harbouring genetic alterations. Multiple EBV-encoded microRNAs have been reported to have immune evasion functions. Genetic alterations in host cells modulated by the expression of EBV genes might be associated the growth properties of infected premalignant epithelial cells. The aims of our study are to find potential biomarkers for future therapy for EBV associated gastric cancer.
导师简介 Biography：
覃青松 2010 在美国爱荷华州立大学兽医学院获得博士学位 ，并在威斯康星大学 麦迪逊分校和宾夕法尼亚州立大学完成了博士后的培训 。2017 年加入汕头大学 医学院，聘为研究员 。现在是人类病毒学和肿瘤学实验室（ LHVO） 的负责人。
Qingsong Qin got his Ph.D at Iowa State University College of Veterinary Medicine, Ames, IA, USA in 2010, and finished hist postdoctoral training at the University of Wisconsin-Madison and Pennsylvania State University. He joined Shantou University College of Medicine in 2017. Now he is a tenure-tracked associate professor and takes charge of the Laboratory of Human Virology and Oncology (LHVO).
代表性文章：
His selected representative publications are listed below:
1. Yueyan Liao, Xiangyu Ke, Tianyi Deng and Qingsong Qin*. The Second-Generation XPO1 Inhibitor Eltanexor Inhibits Human Cytomegalovirus (HCMV) Replication and Promotes Type I Interferon Response. Frontiers in Microbiololgy., 03 May 2021
| https://doi.org/10.3389/fmicb.2021.675112
2. Yixuan Wang, Baixin Chen, Yun Li, Lei Zhang, Yuyi Wang, Shuaibing Yang, Xue Xiao, Qingsong Qin*, The Use of Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors is Associated with a Lower Risk of Mortality in Hypertensive COVID-19 Patients: A Systematic Review and Meta-analysis. Journal of Medical Virology. 2020 Oct 23. doi: 10. 1002/jmv.26625.
3. Yixuang Wang, Yuyi Wang, Yan Chen, Qingsong Qin*. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020 Mar 5. doi: 10. 1002/jmv.25748
4. Xingyu Ke, Qingsong Qin*, Tianyi Deng, Yueyan Liao, Shou-jiang Gao*. Heterogeneous Responses of Gastric Cancer Cell Lines to Tenovin-6 and Synergistic Effect with Chloroquine. Cancers (Basel). 2020 Feb 5;12(2). pii: E365. doi: 10.3390/cancers12020365.
5. Qingsong Qin, Matthew Lauver, Saumya Maru, Eugene Lin, and Aron E. Lukacher. Reducing Polyomavirus Level During Persistent Infection Increases Functionality of Virus-specific Memory CD8 T Cells. Virology. 2017, Jan 4; 502: 198-205.
6. Qingsong Qin, Shwetank Verma, Elizabeth L. Frost, Saumya Maru, and Aron Lukacher. Type I Interferons regulate magnitude and functionality of mouse polyomavirus-specific CD8 T cells in a viral-strain dependent manner. Journal of Virology. 2016 Apr 29;90(10):5187-99.(selected for spotlight section)
7. Qingsong Qin, Rhiannon Penkert, Robert F. Kalejta. Heterologous viral promoters incorporated into the human cytomegalovirus genome are silenced during experimental latency. Journal of Virology. 2013 Sep;87(17):9886-94.
8. Qingsong Qin, Kate Carroll, Craig Hastings, Cathy L. Miller. Mammalian Orthoreovirus escape from host translation shutoff correlates with stress granule disruption and is independent of eIF2a phosphorylation and PKR. Journal of Virology, 2011 Sep; 85(17):8798-8810.
9. Qingsong Qin, Craig Hastings, Cathy L. Miller. Mammalian orthoreovirus particles induce and are recruited into stress granules at early times post infection. Journal of Virology, 2009 Nov; 83(21):11090-10.
管轶 Guan Yi
邮箱及联系电话：13829660990@163.com, yguan@hkucc.hku.hk, 86-754-88900435, 86-13829648992
Email & Contact Number：13829660990@163.com, yguan@hkucc.hku.hk, 86-754-88900435, 86-13829648992
研究方向：
1) 呼吸道病毒的生态学 、流行病学和进化研究
2) 病毒性新发传染病病原研究
3) 抗病毒药物研发（单克隆抗体） Research Field：
1) Ecology, epidemiology and evolution study of respiratory viruses
2) Etiology study on viral emerging diseases
3) Research and development of the antiviral drugs (mAb)
导师简介 Biography：
管轶，香港大学终身讲座教授和明德教授 、汕头大学教授，英国皇家医学院公共 卫生院杰出外籍院士、世界卫生组织高致病性禽流感参比实验室联席主任、香港 大学新发传染性疾病国家重点实验室主任、教育部病毒学与新发传染病国际合作 联合实验室主任 、汕头大学•香港大学联合病毒学研究所所长 、粤港新发传染病 联合实验室主任。
他是 SARS 冠状病毒及其传染源的发现者 、流感病毒研究国际权威，香港特区政 府 、联合国粮农组织 、世界动物卫生组织 、世界卫生组织顾问，也是加拿大盖尔 德纳全球卫生奖（2021）、国家科学技术进步奖特等奖（2017）、何梁何利基金科 学与技术进步奖 、美国国立卫生研究院（ NIH）特别贡献奖 、香港杰出卫生研究 奖 、《时代》杂志全球卫生精英人物 、“亚洲英雄”等荣誉称号的获得者。
其研究集中在流感和其他新发病毒的生态、演化和发病机制上 。已发表同行评审 论文 350 多篇，被引用超过 4.7 万次，专利 40 多项，高引用学术水平指数（high citation / h-index） 104 。根据国际权威机构美国 Thomson 科学信息研究所（汤森 路透）十年研究成果影响力的排名，他在禽流感（2005 年）及 H1N1 流感（2009 年）研究领域个人排名列全世界第 5 及第 4 位，在微生物学大学科研究上（2014 年）全世界总排名第 11 位。他已经连续 7 年被评为“高被引科学家（Highly Cited Researcher）”及全球最具影响力科学家（ 2014-2020）。
Prof. Guan is the Director of Joint Institute of Virology (Shantou University – The University of Hong Kong), Shantou University. His research focuses on the ecology, evolution and pathogenesis of influenza and other emerging respiratory viruses. Over the past decade, his research team has made distinguished contributions to research in virology and to the control of emerging infectious diseases in China and the world. His contribution to the field is reflected in his publication record of over 350 peer-reviewed articles with >47,000 citations and an h-index of 104.
Prof. Guan was ranked as a highly cited researcher (2014-2020) and is ranked 11th in the world in the field of microbiology (Thomson). He is the 2021 John Dirks Canada Global Health Award Laureate. In 2007, he was elected a Fellow of the Faculty of Public Health of the Royal Colleges of Physicians of the United Kingdom. He has obtained substantial grant funding from the NIH of the USA, the Welcome Trust fund and the WHO as well as from local government sources and private foundations. “Time” magazine of the USA has twice featured him, first as one of 18 “Global Health Hero” and later as an “Asian Hero” .
病毒学 Virology
汕头大学·香港大学联合病毒学研究所成立于 2016 年 ，其前身为 2001 年在世界 卫生组织支持下成立的汕头大学医学院/香港大学医学院联合流感研究中心 。经 过近二十余年的建设，研究所已培育了一支拥有 70 余名国内外科研人员的科研 队伍 ，并建设了 8000 多平方米 、可开展病毒学 、病理学 、免疫学 、分子生物学 等多种学科研究工作的实验室，还装备了一个 1000 余平方米的 II+级至 III+级生
物安全实验室。
研究所的主要研究方向有：
1) 病毒性新发传染病的溯源 、进化和流行病学研究；
2) 病毒的致病性 、传播性与跨种属传播机制研究；
3) 病毒的诊断及应用研究。
迄今，研究所已在顶级学术期刊发表多篇论文，包括 Nature 6 篇 ，Science 3 篇。 2017 年研究所科研项目“ 以防控人感染 H7N9 禽流感为代表的新发传染病防治体 系重大创新和技术突破”获得国家科学技术进步奖特等奖。
Joint Institute of Virology (Shantou University – The University of Hong Kong) was established in 2016. Its predecessor was STU/HKU Joint Influenza Research Center that established in 2001 with the support of the World Health Organization. Now the Institute has cultivated a scientific research team with more than 70 scientific researchers. The research building of the Institute covers over 8,000 square meters, providing an international platform for research work in virology, pathology, immunology, and molecular biology. The Institute also equips with a Level II and a level III Biosafety Laboratory for virology studies.
The main research directions of the Institute are:
1) Origin, evolution and epidemic of respiratory viruses that causing emerging infectious diseases;
2) Pathogenicity, transmissibility and interspecies transmission mechanism of viruses;
3) Diagnosis and application of viruses.
So far, the Institute has published papers in professional journals, including 6 in Nature and 3 in Science. In 2017, scientific research project "Major Innovation and Technological Breakthrough in the Prevention and Control System of Emerging Infectious Diseases Represented by the Prevention and Control of human infection with H7N9 avian influenza" won the Special Prize of the National Science and Technology Progress Award.
唐乐 Le Tang
邮箱及联系电话：letang@stu.edu.cn, le.tang@ucalgay.ca, 86-13199571843
Email & Contact Number：letang@stu.edu.cn, le.tang@ucalgay.ca, 86-13199571843
研究方向 ：导致不同细菌病原体产生的分子进化 致病性革兰阴性细菌六型分泌系统
Research Field：Molecular Evolution of bacteria leading to distinct pathogens
Type VI secretion system in Gram-negative bacterial pathogens
导师简介 Biography：
唐乐，医学博士， 汕头大学医学院病原生物学教研室 ，副教授 。 2010 年本 科毕业于哈尔滨医科大学 ，主修预防医学 ，辅修临床医学 。2015 年获哈尔滨医 科大学病原生物学博士学位。博士在读期间由黑龙江省教育厅专项经费资助赴美 国普渡大学学习交流一年。毕业后先后在加拿大卡尔加里大学和澳门大学做博士 后研究工作 。研究领域为微生物病原学与基因组进化 。 以第一/共同第一或通讯 作者发表 SCI 论文 13 篇 ，并以第一作者或合作者为《Reference Module in Life Sciences》（生命科学百科全书）以及《Molecular Medical Microbiology》 (Second Edition) （分子医学微生物学）等国际著名专著贡献有关章节。作为项目负责人 主持中国以及加拿大省部级项目 5 项。现任 Frontiers in Molecular Biosciences SCI 学术期刊编委 ，为 Briefings in Bioinformatics 、Emerging Microbes & Infections 、 Journal of Medicinal Plant Research 等 SCI 学术期刊审阅稿件。
Le Tang is an associate professor at Shantou University Medical College. She obtained her MD and PhD degree from Harbin Medical University in 2010 and 2015. During her PhD program, she was supported by Heilongjiang Provincial Innovation Endowment Award for International Academic Exchanges for a research collaborative visit to Purdue University, USA, for one year. After graduation, she worked as a postdoctoral fellow at University of Calgary, Canada, from 2015-2018 and University of Macau from 2019-2021. Dr. Tang’s research focuses on understanding how pathogens evolve and the molecular evolution of bacteria leading to distinct pathogens, with 17 research papers published in Genomics, BMC Genomics, BMC Microbiology, etc. She was supported by national or provincial grant agencies of China and Canada, including Natural Science Foundation of China, Alberta Innovates Health Solutions, etc. She is currently a topic editor at Frontiers in Molecular Biosciences and she reviews manuscripts for several journals including Briefings in Bioinformatics, Emerging Microbes & Infections, etc.
David J. Kelvin
邮箱及联系电话：dkelvin@jidc.org, david.kelvin@dal.ca,
1-647-5293556 ，86-0754-88573991
Email & Contact Number：dkelvin@jidc.org, david.kelvin@dal.ca, 1-647-5293556 ，86-0754-88573991
研究方向：
1) 新发传染病
2) 前列腺癌
3) 远古病原体
4) 实验疗法
5) 检测病原体的计算方法
Research Field：
1) Emerging Infectious Diseases
2) Prostate Cancer
3) Ancient Pathogens
4) Experimental Therapeutics,
5) Computational Methods for Pathogen Discovery
导师简介 Biography：
Kelvin 博士是一位国际公认的科学家，在 Nature，Nature Medicine，Science，Cell， J. Exp. Med.，J. Clin. Invest.等期刊上发表学术论文一百多篇。Kelvin 博士和他的 国际团队（中国汕头、意大利萨萨里和加拿大哈利法克斯等）专注于研究新发传 染病及其在未来和过去流行病中的作用。其中一些研究运用基因组学和计算方法 来检测新发病原体和治疗方法。随着 COVID-19/SARS-CoV-2 转变为许多国家的 地方流行性疾病，Kelvin 博士及其团队当前的研究项目旨在研究 SARS-CoV-2、 环境、人类和动物行为以及区域流行病之间的动态关系。其近期研究发现，严重 的 COVID-19 与 SARS-CoV-2 病毒血症和全身感染相关 。免疫系统未能将早期 SARS-CoV-2 感染控制在局部感染，这在目前是一个重要的研究领域。Kelvin 博 士研究团队及其国际合作者利用计算模式来识别具有阻断 SARS-CoV-2 感染和 复制潜力的抗病毒分子。利用世界各地药用化合物的研究策略在将传统文化与现 代医学实践联系起来方面具有很大的研究前景。为更好地了解全球环境变化和温 度波动对微生物组的影响，Kelvin 博士研究团队正在从加拿大北部偏远地区和其 他环境敏感地区的动物 、植物和水源中生成微生物组（病毒组 、细菌组等）， 以 创建物种变化的时间历史 ，并利用计算方法预测全球环境变化对未来的影响。
Dr. Kelvin is an internationally recognized scientist who has published in many top tiered journals including Nature, Nature Medicine, Science, Cell, J. Exp. Med., J. Clin. Invest., and several clinically based journals. With international teams located in Shantou, China, Sassari, Italy, and Halifax, Canada, Dr. Kelvin and his Colleagues focus on the discovery of emerging infectious diseases and their role in future and past epidemics and pandemics. Several projects employ genomic and computational modalities for the discovery of novel pathogens and therapeutics. With COVID-19/SARS-CoV-2 now an endemic problem in many countries, ongoing research projects aim to understand the dynamic relationship between SARS-CoV-2, environment, human and animal behavior and regional epidemics. Dr. Kelvin and colleagues have recently discovered that severe COVID-19 is associated with SARS-CoV-2 viremia and a systemic infection. The failure of the immune system to limit early SARS-CoV-2 infections to a localized infection is currently an important field of study. Dr. Kelvin’s research team and international collaborators have also utilized computational modalities for identifying anti-viral molecules with the potential for blocking SARS-CoV-2 infection and replication. Drawing on medicinal compounds derived from exotic regions in the world, this strategy holds great promise in linking traditional cultures with modern medical practices. In an attempt to better understand the impact of Global Environmental Change and temperature fluctuations on microbiomes, Dr. Kelvin’s team is generating archival microbiomes (viromes, bacteriomes, etc.) from animal, plant and water sources in remote northern regions in
Canada and other environmentally sensitive regions to create a temporal history of species change and using computational methods predict the future impact of Global Environmental Change.
郭九标 Jiubiao Guo
邮箱及联系电话：guojiubiao@163.com ，86-13143844926
Email & Contact Number：guojiubiao@163.com ，86-13143844926
研究方向: 病原感染与免疫以及药物开发
Research Field：Pathogen infection and host immune response mechanism, and anti-pathogen drugs development
导师简介 Biography：
汕头大学医学院和第一附属医院双聘教授 。2015 年毕业于香港理工大学 ，获哲 学博士学位。主要研究方向为病原微生物感染与免疫、药物及相关快速检测技术 开发等。主持国家及市厅级项目 6 项，经费资助金额近 500 万元人民币，在 mBio、 Journal of Biological Chemistry 、Bioelectrochemistry 和 Frontiers in Microbiology 等 SCI 期刊上上发表学术论文 30 余篇，申请国家专利 10 余项，并获得授权专利 2 项 。另外，参与指导硕士和博士研究生 3 名。
Jiubiao Guo is a double-appointed professor of Shantou University School of Medicine and the First Affiliated Hospital. Dr. Guo graduated from the Hong Kong Polytechnic University in 2015 with a doctorate degree in philosophy. His research is mainly focusing on pathogenic microbial infection and host immune response, drug and related rapid detection technologies development. He has in charge of 6 national or departmental projects, with a funding amount of about 5 million yuan, published more than 30 academic papers in SCI journals such as mBio, Journal of Biological Chemistry, Bioelectrochemistry and Frontiers in Microbiology, and have applied for more than 10 China patents, two of them have been authorized. In addition, he has participated in the supervision of three master's and doctoral students in the past years.
王嵬 Wei Wang
邮箱及联系电话：wei.wang@ecu.edu.au, 86-13911160290
Email & Contact Number：wei.wang@ecu.edu.au, 86-13911160290
研究方向: 糖基医学 、糖基组学
Research Field：Glycomedicine, Glycogenomics
导师简介 Biography：
王嵬 ，汕头大学医学院特聘教授，世界华人医师协会 (WACD) 副会长 ，英国皇 家医学院院士 (FRSM) ，英国皇家内科医生学会公共卫生学院院士 (FFPH) ，英 国皇家生物学会会士 (FRSB)，世界卫生组织 (WHO) 公共卫生基因组学专家委 员会委员， 国家经济合作组织 (OECD) 公共健康基因组专家指导委员会委员 ， 欧洲预防与精准医学协会 (EPMA) 澳大利亚代表 ，全球健康流行病学工作组 (GHERG) 专家委员会委员 ，人类糖基组计划 (HGP) 组委会委员 。 曾任澳大利 亚埃迪斯科文大学副校长 。他提出“旁中心法则 ”，糖分子可能是“ 中心法则 ” 之外的另一生命密码 。王教授在全球健康 、遗传流行病学和糖基组学领域发表 300 多篇论文/综述/述评，代表性成果发表在《Lancet》、《Science》、《Nature Genetics》、《The New England Journal of Medicine》等。
Prof. Wei Wang, MD, PhD, FFPH, FRSB, FRSM, is an ex-Pro Vice Chancellor of Edith Cowan University, a Distinguished Overseas Professor of Shantou University Medical College, a Guest Professor of Capital Medical University and an Adjunct Professor of Shandong First Medical University. He holds the honorary positions as fellow of the Public Health Faculty, Royal College of Physicians, and Royal Society of Medicine, UK. His contributions to medical science include service as a Member of the expert panel advising the World Health Organization (WHO) on its ‘Grand Challenges in Genomics for Public Health in Developing Countries’, a Steering Committee Member of Economic Co-operation and Development (OECD) Initiative on Public Health Genomics, the national representative of Australia and China for European Association of Preventive, Predictive and Personalized Medicine (EPMA), and he is a member of Secretariat, International Society of Global Health (ISoGH) as well a Steering Committee Member of the Human Glycome Project (HGP). Prof. Wang is the academic editor of the journal of PloS ONE (PLOS), associate editor of EPMA Journal (Nature-Springer), and regional editor of Journal of Global Health (Edinburgh University Press), OMICS: A Journal of Integrative Biology (Mary Ann Liebert, Inc), Journal of Human Hypertension (Nature), and editor of Engineering (Medicine Section). He has published over 300 scientific papers in prestigious journals including Science, Nature Genetics and The Lancet.
杨霜 ShuangYang
邮箱及联系电话： shuangyang@stu.edu.cn, 86-13405064922
Email & Contact Number：shuangyang@stu.edu.cn, 86-13405064922
研究方向: 糖蛋白组学，糖核酸组学 ，肠炎-肿瘤
Research Field：Glycoproteomics, Nucleic acid glycosylation, IBD-CRC
导师简介 Biography：
杨霜博士是糖生物学、先进质谱与转化生物标志物发现等交叉领域的全球公认专 家与领军科学家，长期致力于揭示异常糖基化在人类疾病中的根本作用。在其 22 年的卓越学术生涯中，他始终聚焦于前沿分析技术的开拓，特别是在高通量 糖基化分析新型质谱方法的开发方面作出重要贡献。杨博士最具奠基性与开创性 的成果体现在糖基 DNA 与糖基 RNA 这两个新兴领域，成为探索核酸糖基化在 细胞生物学及疾病进展中功能与调控机制的引领者。在美国期间（2003–2020 年）， 他的研究获得联邦政府大力支持，曾作为首席研究员成功主持美国国立卫生研究 院（NIH）小企业创新研究（SBIR）项目，并贡献于六项 NIH 资助课题，体现 了其研究的国家重要性与技术创新性。此后，杨博士回国任苏州大学药学院特聘 教授、临床质谱中心主任，并兼任苏州大学附属第二医院及第四医院兼职教授， 成功将分析专长转化为临床应用，推动多项靶向生物标志物发现项目，致力于建 立早期、疾病特异性的诊断与预后标志物。他于 2025 年加入汕头大学医学院糖 组学研究院，当前研究涵盖多个关键健康领域，包括肺癌早期唾液岩藻糖标志物 筛选、胰腺癌尿液与消化道外泌体标志物鉴定，以及帕金森病、阿尔茨海默病等 神经退行性疾病在可及生物体液中的早期症状标志物探索。
杨博士科研成就卓著，已在《自然·生物技术》《自然·评论》《化学科学》《分析 化学》等顶级期刊发表 100 余篇同行评审论文，总被引超 5000 次，h 指数达 45 ， 并拥有 25 项公开与授权专利。他还积极投身学术服务，担任《糖缀合物杂志》 《癌症治疗与研究通讯》《生物标志物科学与技术进展》等期刊编辑，曾作为 NIH 与 FDA 糖科学研究日的分会主席与评委、美国化学会（ACS）秋季全国会议分 析化学分会主席，以及美籍华人质谱学会（CASMS）执行委员会成员。这些角 色不仅彰显其作为高产科学家的影响力，也体现他在分析糖生物学与临床蛋白质 组学领域作为学术领袖与管理者的持续奉献，始终以技术创新推动人类健康进步。
Dr. Shuang Yang is a globally recognized expert and leading scientist in the synergistic fields of glycobiology, advanced mass spectrometry (MS), and translational biomarker discovery, dedicated to unraveling the fundamental roles of abnormal glycosylation in human disease. With a distinguished 22-year career, his work is characterized by a robust focus on pioneering cutting-edge analytical technologies, particularly the development of novel MS-based methods for high-throughput glycosylation profiling. Dr. Yang's most foundational and pioneering contributions extend into the relatively uncharted territories of GlycoDNA and GlycoRNA, establishing him as a leader in investigating the functional and regulatory roles of nucleic acid glycosylation in cell biology and disease progression. His foundational tenure in the United States (2003–2020) was highly productive, marked by significant federal support, including securing and leading an NIH Small Business Innovation Research (SBIR) grant as Principal Investigator, and contributing significantly to six NIH-funded sub-projects, reflecting the national importance and
technological innovation of his research. Following this success, Dr. Yang returned to China to assume a leadership role as a distinguished Professor at the College of Pharmaceutical Sciences at Soochow University and the Director of the Center for Clinical Mass Spectrometry, while also holding an Adjunct Professorship at the Affiliated No. 2 & 4 Hospital. In this capacity, he has successfully translated his analytical expertise into direct clinical applications, driving targeted biomarker discovery programs to establish early, disease-specific diagnostic and prognostic markers. He joined the Institute of Glycomics at Shantou University Medical College in 2025. His current translational projects span critical health areas, including screening fucose markers in saliva for early lung cancer detection, identifying pancreatic cancer markers in urine and digestive tract exosomes, and actively searching for early symptomatic markers of neurodegenerative diseases such as Parkinson's and Alzheimer's in accessible biofluids. His scientific impact is substantial and globally recognized, reflected in an impressive publication record of over 100 peer-reviewed articles, appearing in top-tier journals such as Nature Biotechnology, Nature Reviews, Chemical Science, and Analytical Chemistry. This body of work has garnered over 5,000 citations, leading to an h-index of 45, and his technological innovations have resulted in over 25 patent disclosures and issued patents. Beyond his research and academic leadership, Dr. Yang contributes extensively to the scientific community as an Editor for prominent journals including Glycoconjugate Journal, Cancer Treatment and Research Communications, and Advances in Biomarker Sciences and Technology. He has also served in significant organizational roles, including as a session chair and judge for the NIH & FDA Glycoscience Research Day, an Analytical Chemistry Session Chair for the ACS National Fall Meeting, and an active member of the Chinese American Mass Spectrometry Society (CASMS) Executive Committee, solidifying his role not only as a prolific scientist but also as a dedicated steward and intellectual leader in the global field of analytical glycobiology and clinical proteomics, with a clear mission to advance human health through technological innovation.